U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google's parent company ...
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...
Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...
Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...
Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...
Eli Lilly (NYSE: LLY) Q3 2024 Earnings Call Oct 30, 2024, 10:00 a.m. ET Ladies and gentlemen, thank you for standing by and ...
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...
Mookie Betts speaks out after fan tries to steal ball from La Dodgers star ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback